Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone marker–directed zoledronic acid vs standard schedule in metastatic breast cancer
2005-001376-12Phase 4Completed
- Sponsor
- University of Sheffield
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of zoledronic acid in breast cancer and bone metastases (2 arms), sponsored by University of Sheffield. Primary endpoint: Skeletal-related events frequency and timing. Started Jun 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancerbone metastases
Beyond the preview
Go deeper on 2005-001376-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001376-12.